Peripheral Dual Opioid Agonist for Inflammatory Pain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid analgesics, such as morphine, are ineffective for certain types of pain like inflammatory and chronic pain due to down-regulation of mu-opioid receptors and activation of non-opioid pain pathways, leading to incomplete relief, addiction, and undertreatment, with significant public health concerns.
Innovation Solution
A dual-acting opioid agonist, Compound 1, that activates kappa and delta opioid receptors peripherally without crossing the blood-brain barrier, providing synergistic pain relief without the central nervous system side effects associated with traditional opioids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional mu-opioid agonists like morphine are used for pain treatment, then pain relief is achieved, but addiction and central nervous system side effects occur
Solution Approach 1:
The patent divides the opioid receptor targeting approach into two separate components: peripheral kappa-opioid receptor agonism for pain relief and avoidance of central mu-opioid receptor activation to prevent addiction. This segmentation allows the drug to achieve analgesic effects while eliminating the harmful central nervous system side effects associated with traditional opioids.
Solution Approach 2:
The compound is designed to have selective peripheral action at kappa-opioid receptors in the nervous system, creating a localized effect that provides pain relief without affecting central mu-opioid receptors in the brain. This local quality ensures that the therapeutic benefit is achieved at the site of action while avoiding harmful systemic effects.
2Reliability
If mu-opioid agonists are used for chronic pain, then some pain relief is achieved, but effectiveness decreases due to receptor down-regulation
Solution Approach 1:
Instead of continuing to use mu-opioid agonists that lose effectiveness over time due to receptor down-regulation, the patent inverts the approach by using kappa-opioid receptor agonists at peripheral sites. This alternative pathway maintains effectiveness for chronic pain treatment without the tolerance and dependence issues that limit the duration of action for traditional opioids.
3Object-affected harmful factors
If peripherally-restricted opioids are used to avoid CNS side effects, then addiction risk is reduced, but pain relief effectiveness may be compromised
Solution Approach 1:
The patent merges the benefits of peripherally-restricted action (reduced addiction risk) with effective pain relief by combining kappa-opioid receptor agonism with specific molecular structure features that ensure peripheral selectivity. The compound achieves both goals simultaneously: it provides reliable analgesia through peripheral kappa-receptor activation while maintaining low addiction risk due to minimal central nervous system penetration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Compound 1 offers effective pain relief comparable to central-nervous system-acting opioids like morphine but with reduced risk of addiction and side effects, effectively treating inflammatory and chronic pain conditions.
Implementation Method 1
The opioid activates both the kappa and delta opioid receptors to provide synergistic reduction in pain: dual agonism
Implementation Method 2
A dual-acting opioid agonist, Compound 1, that activates kappa and delta opioid receptors peripherally without crossing the blood-brain barrier
Data Source
AI summary
The present disclosure teaches the use of a dual-acting opioid agonist for the treatment of pain (e.g., inflammatory pain). The opioid agonist activates both the kappa and delta opioid receptors to provide synergistic reduction in pain. The opioid agonist is peripherally restricted and does not cross the blood-brain barrier.